BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29039746)

  • 21. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
    Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
    Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in-frame deletion in the NS protein-coding sequence of parvovirus H-1PV efficiently stimulates export and infectivity of progeny virions.
    Weiss N; Stroh-Dege A; Rommelaere J; Dinsart C; Salomé N
    J Virol; 2012 Jul; 86(14):7554-64. PubMed ID: 22553326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
    Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
    Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
    Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
    Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
    Akladios C; Aprahamian M
    Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
    Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
    Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
    Bretscher C; Marchini A
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
    Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
    Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
    Bhat R; Rommelaere J
    BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
    Bhat R; Dempe S; Dinsart C; Rommelaere J
    Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.
    Pittman N; Misseldine A; Geilen L; Halder S; Smith JK; Kurian J; Chipman P; Janssen M; Mckenna R; Baker TS; D'Abramo A; Cotmore S; Tattersall P; Agbandje-McKenna M
    Viruses; 2017 Oct; 9(11):. PubMed ID: 29084163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
    Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
    Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
    Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
    Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
    Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
    Viruses; 2021 May; 13(6):. PubMed ID: 34071585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
    Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
    EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.
    Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM
    Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
    Angelova AL; Aprahamian M; Grekova SP; Hajri A; Leuchs B; Giese NA; Dinsart C; Herrmann A; Balboni G; Rommelaere J; Raykov Z
    Clin Cancer Res; 2009 Jan; 15(2):511-9. PubMed ID: 19147756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.